We have substantially upgraded the RNAactDrug 2.0 database through large-scale data expansion and enhanced analytical capabilities, including:
●Integrates large-scale pharmacogenomic datasets from GDSC, CellMiner, CCLE, and PubChem, covering 1346 cancer cell line samples at four molecular levels (expression, copy number variation, methylation, and mutation) for systematic characterization of drug sensitivity-related molecular features.
●Incorporates 30,890 drugs, 38,908 RNA molecules (including 19,887 mRNAs, 17,058 long non-coding RNAs (lncRNAs), and 1,963 microRNAs (miRNAs)), and 22,800,375 RNA molecule–drug sensitivity associations across four molecular layers.
●Constructs an enhancer-mediated epigenetic regulation–drug sensitivity association landscape, incorporating 15,991 drugs, 54,393 enhancer elements, 25,889 enhancer target genes, and 23,635,715 enhancer–drug sensitivity associations.
●Combines TCGA multi-omics data spanning 10,237 tumor samples, and matched clinical profiles, alongside 3,843,186 cells from 208 scRNA-seq datasets across 38 tissues and 44 cancer types for single-cell drug sensitivity analysis.
●Upgrades search and browse functionalities to enable efficient and user-friendly data retrieval and exploration.
●Provides 7 analytical tools for functional annotation, pan-cancer analysis, tumor microenvironment profiling, single-cell trajectory and CNV analysis, and enhancer regulatory network construction.
RNAactDrug 2.0 has evolved from a single drug–RNA association database into a comprehensive multi-omics and multi-scale analytical platform. Leveraging a substantially optimized multi-dimensional search system and massively expanded data resources, it enables efficient and systematic mining of drug sensitivity-related RNAs and enhancer regulatory elements, while providing crucial support for uncovering drug resistance biomarkers and developing personalized therapeutic strategies.